Trial Profile
A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety and Efficacy of MK0653 When Added to Current Regimen in Patients With Homozygous Sitosterolemia.
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 05 May 2022
Price :
$35
*
At a glance
- Drugs Ezetimibe (Primary)
- Indications Sitosterolaemia
- Focus Therapeutic Use
- Sponsors Organon
- 02 Feb 2010 New trial record